Bunge Global BG
Consumer Defensive · Agricultural Farm Products · Synthos Deep Dive · 2026-07-03
The Overview
Bunge is one of the handful of giant companies that buys crops from farmers — soybeans, wheat, canola — moves them around the world, crushes oilseeds into cooking oil and animal-feed meal, and sells to food and biofuel makers. It just merged with another huge grain trader, Viterra, which is why its sales nearly doubled to about $70 billion last year. It is a real, essential business, but a low-margin one: out of every $100 of sales it keeps only about $4.50 as gross profit and roughly $1 as actual net profit.
Is the stock cheap or expensive? Cheap — you're paying about 11 times next year's expected earnings, well below the market. But cheap-for-a-reason: profits swing hard with crop prices and "crush margins" that Bunge can't control, and the company took on a lot of debt to buy Viterra.
Our verdict is Watch — a wait-and-see. It's not broken and it's not expensive, but there's no engine pulling it steadily higher, so it belongs on a list to buy on weakness or once the merger clearly pays off, not as a set-and-forget holding.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). The stock is cheap and doesn't swing wildly day-to-day, but the business is cyclical and carries meaningful debt after the merger, so a bad crop year would hurt.
- Growth Quality 4/10 (below average). Earnings should bounce back as the merger delivers savings, but this is a low-margin, up-and-down business, not a steady grower.
- Exponential Potential 3/10 (low). It's already big in a slow-growing, GDP-linked market. Don't expect it to multiply.
The one big worry: a downturn in crop-trading and crushing margins — which Bunge does not control — while it's still carrying elevated debt from the Viterra deal.
Putting a number on it: our fair-value estimate is $120 against a current price of $115.48 — real upside if our numbers are right.
Our summary metrics
Low beta (0.62) & cheap on forward EPS, but 6.6× trailing net-debt/EBITDA post-Viterra, razor-thin 4.5% gross margin, and deep commodity cyclicality.
Forward EPS recovers on Viterra synergies but is cyclical, not secular — 4.5% gross margin, ~4.7% ROE, no durable moat.
A $21B commodity crusher/trader in a mature, GDP-linked TAM — cheapness, not exponential growth, is the story.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A $21B commodity crusher/trader in a mature, GDP-linked TAM — cheapness, not exponential growth, is the story.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $134 (high $150 / low $117; 21 Buy · 4 Hold · 0 Sell) — context, not our anchor |
| Valuation | 24.6× trailing GAAP EPS · ~11× FY26E · ~10× FY27E · EV/S 0.45× · EV/EBITDA 15.3× TTM |
| Technicals | Downtrend/oversold — $106, −19% off 52-wk high, below 50-DMA, RSI 19.5 (deeply oversold), −17% 3-mo (SPY +14%) |
| Conviction | Low — 0 expert voices in the KB; call rests entirely on fundamentals & quant |
| Position sizing | Small satellite/value sleeve only, ~1–2% if bought; not a core holding |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for BG — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $115.48, 2% above the 50-day average ($113), 2% above the 200-day average ($114) — an uptrend. 12% below the 52-week high of $131, 50% above the 52-week low of $77.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $115.48 is currently inside the band (band $106–$118).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 55.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.32, positive momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = BG · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Bunge Global S.A. (NYSE: BG) is a ~200-year-old (founded 1818) international agribusiness and food company, now domiciled in Switzerland with US operational HQ in Chesterfield, Missouri. It is one of the "ABCD" global grain majors (ADM, Bunge, Cargill, (Louis) Dreyfus). CEO Gregory Heckman; ~34,000 employees; fiscal year ends December 31. In 2025 Bunge closed its transformative merger with Viterra, roughly doubling reported revenue (FY24 $53.1B → FY25 $70.3B) and the diluted share count (~134M → ~193M shares).
The business runs in four segments:
- Agribusiness — sourcing, storing, transporting, processing and selling oilseeds (soy, canola, rapeseed, sunflower) and grains; the core crush-and-trade engine.
- Refined & Specialty Oils ("Edible Oil Products") — bottled and bulk oils, shortenings, margarines for food manufacturers and foodservice.
- Milling — wheat and corn flours, mixes, specialty grains.
- Sugar & Bioenergy — sugar, ethanol and bagasse-fired electricity (largely a Brazilian JV).
Revenue mix (FMP product segmentation). The FY2025 segmentation in our data is incomplete post-Viterra (it reports only Milling Products $1.55B + Other), so the cleaner read is FY2024: Agribusiness $28.0B (~53%) · Edible Oil Products $12.8B (~24%) · Milling $1.56B · Sugar & Bioenergy $130M · Fertilizer $54M. Agribusiness — the low-margin crush/trade core — is the majority of the company.
Geography (FY2024, FMP): Europe ~$25.4B, United States ~$14.2B, Asia-Pacific ~$6.2B, Brazil ~$3.8B, Canada ~$2.2B, Argentina ~$0.86B. Genuinely global and commodity-diversified, which dampens single-region risk but ties results to global crop cycles and FX.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of BG in the Synthos knowledge base. total_claims is 0; there are zero net-bullish or cautionary voices distilled for this name. Accordingly, this deep dive carries no conviction claims and cites no claim_ids — it would be dishonest to manufacture any.
The verdict is therefore fundamentals- and quant-driven only: the financials, analyst estimates, valuation and technicals in the FMP data set, judged against the Synthos house framework. Where the Street's own view matters, we show it as context (§6): sell-side is constructive (21 Buy / 4 Hold, consensus target $134, ~+26%), but sell-side price targets are not our anchor, and BG's FMP letter rating is only B- (overall quality score 2/5).
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Low beta (0.62) and a cheap forward multiple cushion the downside, but trailing net-debt/EBITDA 6.6× (elevated post-Viterra), a 4.5% gross margin, negative FY25 FCF, and deep commodity cyclicality raise it. |
| Growth Quality | 4 · Below Average | Forward EPS recovers sharply on Viterra synergies ($9.38 FY26E vs $4.96 FY25 GAAP), but it's a cyclical rebound off a trough, not secular growth — ~4.5% gross margin, ~4.7% ROE, ~4.3% ROIC, no durable moat. |
| Exponential Potential | 3 · Low | A $21B commodity crusher/trader in a mature, GDP-linked TAM. Revenue growth beyond the Viterra step-up is low-single-digit; the story is cheapness and synergy, not exponentiality. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. Because BG is a low-multiple cyclical, the swing factor is as much the exit multiple (crush-cycle sentiment) as the EPS itself.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Viterra synergies over-deliver, crush/oilseed margins normalize up, biofuel-driven soybean-oil demand firms. FY27E EPS beats to ~$12.5 (vs $11.13 cons); cyclical multiple re-rates to ~12×. | ~$150 (+41%) |
| Base (our anchor) | Synergies land roughly as guided; crush margins mid-cycle. FY27E EPS ~$11.1; a cyclical agribusiness earns a mid-cycle ~11×. | ~$120 (+13%) |
| Bear | Crush-margin down-cycle, weak South American crop or FX drag, synergy slippage; EPS misses to ~$8.5 and the multiple de-rates to ~9× as leverage stays elevated. | ~$78 (−27%) |
Synthos fair value = the base case, ~$120 (+13%), with the full $78–$150 span as the honest range. This anchor sits below the Street's $134 consensus — we discount the multiple more for cyclicality and post-Viterra leverage, and we do not extrapolate synergy upside as confidently as the sell side. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). BG is neither — it is a cyclical value name:
- Forward growth: the FY25→FY26E revenue jump ($70.3B → ~$91.1B, +30%) is almost entirely the Viterra acquisition annualizing, not organic acceleration. Beyond that, revenue is essentially flat-to-low-single-digit (FY26E $91.1B → FY27E $94.5B → FY28E $92.7B — i.e. down in FY28E). EPS recovers off a cyclical trough ($4.96 FY25 GAAP → $9.38 FY26E → $11.13 FY27E → $11.88 FY28E) then flattens.
- Acceleration (2nd derivative): negative on revenue once the deal laps; EPS growth decelerates from a synergy-driven +89% (FY26E vs FY25) toward high-single-digit. No sustained acceleration.
- Room to run: the addressable market (global grain trade, oilseed crush, edible oils) is enormous in dollars but mature and GDP/population-linked — it does not compound at tech-like rates, and Bunge already has global scale. Market cap $21B is small vs the TAM in absolute terms, but the TAM itself doesn't grow exponentially, so "room to run" is limited to share gains and margin normalization.
- Reinvestment runway: capital-intensive (FY25 capex ~$1.7B) with returns on invested capital in the low-single-digits (~4.3% TTM) — reinvestment does not generate exponential value; it maintains a cyclical asset base.
Exponential Potential: Low (3/10). BG is a cheapness-and-synergy story, not a growth story. Owned correctly, it's a mean-reversion/value holding, never a multibagger bet.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $70.3B, +32.4% YoY — but this is the Viterra step-up, not organic. FY24 $53.1B, FY23 $59.5B, FY22 $67.2B. The base is cyclical, not steadily rising: 2023 was a peak, 2024 a dip, 2025 up on M&A.
- Margins (thin, by design): gross 4.5% FY25 (5.2% TTM), operating ~1.5%, net ~1.2% FY25 (0.85% TTM). This is a commodity-throughput business — pennies on the dollar, made up on volume.
- Earnings (cyclical): FY25 net income $819M, EPS $4.96 (GAAP) — well below FY24 ($1.14B, $8.09) and the FY23 peak ($2.24B, $15.07). Note the sharp share-count rise (Viterra) mechanically dilutes EPS. Quarterly EPS is volatile: Q1'26 $0.35, Q4'25 $0.49, Q3'25 $0.85 — but the earnings-calendar adjusted prints beat (Q1'26 adj $1.83 vs $0.88 est; Q4'25 $1.99 vs $1.81) — a reminder GAAP and adjusted diverge materially here due to mark-to-market and deal items.
- Cash flow (the yellow flag): FY25 operating CF only $800M, capex −$1.72B, plus $3.06B of acquisitions → free cash flow −$923M. FCF was +$524M FY24 and +$2.19B FY23 — the negative FY25 is Viterra-integration-driven, but it means the dividend (~$459M paid) was not covered by FCF this year. Watch for FCF turning positive as integration capex rolls off.
- Balance sheet: total debt $15.9B, net debt $14.7B, trailing net-debt/EBITDA 6.6× — elevated, reflecting the Viterra financing and a trough-EBITDA denominator. On FY26E EBITDA (~$4.47B) forward net-debt/EBITDA is a more comfortable ~3.3×, but the deleveraging is a forward assumption. Current ratio 1.6×, interest coverage ~3.1× — serviceable but not fortress. Investment-grade, but leverage is a genuine watch item.
6. Valuation — priced in or room?
BG is cheap on forward earnings and sales, rich-looking on trailing GAAP and cash flow — classic cyclical distortion:
- Trailing: 24.6× TTM GAAP EPS looks high, but that's a trough-earnings artifact; price-to-sales is 0.26× and EV/sales 0.45× (razor-thin, as expected for a trader).
- Forward: ~11× FY26E EPS ($9.38) and ~10× FY27E ($11.13) — genuinely inexpensive vs the market and roughly in line with agribusiness peers.
- EV/EBITDA: 15.3× TTM (trough EBITDA); on FY26E EBITDA (~$4.47B) it's ~8× — cheap.
- Yield: dividend $2.82, 2.65% yield, but 73% GAAP payout and uncovered by FY25 FCF — sustainable only if earnings/FCF recover as expected.
- Book: price/book 1.29×, near tangible book — limited asset-value cushion but not stretched.
Reverse read: at ~11× forward, the market is pricing a muted cyclical recovery and some skepticism on synergy delivery — not euphoria. Street targets (context): consensus $134 (high $150, low $117; 21 Buy / 4 Hold). Our $120 base is more conservative than consensus because we haircut the multiple for leverage and cyclicality. Not a value trap, but not a screaming bargain either — a fair-priced cyclical.
7. Technicals (from the FMP tech block)
- Trend: down / corrective. $106.46 sits below the 50-DMA ($121.8) and just below the 200-DMA ($108.5) — the 50 rolling under the 200 is a bearish (death-cross) posture. MACD −4.85 (negative).
- Location: −19.0% off the 52-week high ($131.4) and +45.8% off the 52-week low ($73.0); max drawdown from peak −19.0%. Mid-range, well off highs.
- Momentum: RSI(14) 19.5 — deeply oversold (<30). This is a washed-out reading; mean-reversion bounces often follow, but oversold can persist in a downtrend.
- Relative strength: −17.0% 3-mo vs SPY +13.7% / QQQ +22.0% — sharp recent underperformance. Over 12 months BG +32.7% vs SPY +20.6%, so the longer trend is still ahead of the market; the pain is recent (post-peak correction).
- Read: technicals are weak and oversold — the price action disagrees with the cheap-valuation thesis right now. For a value buyer this is a potential entry zone if fundamentals hold; for a momentum lens it's a falling knife. Prudent approach: wait for stabilization above the 50-DMA or a clean earnings catalyst rather than catching the oversold reading blind.
8. Moat & competitive position
Bunge's "moat" is scale and logistics, not pricing power. Its edge is a global network of origination, storage, port and crush assets (now enlarged by Viterra) that is expensive to replicate — but it competes head-to-head with equally large rivals (ADM, Cargill, Louis Dreyfus) in a business where the product is a commodity and margins are set by crush spreads and crop cycles, not brand or switching costs. Returns on capital are structurally low (ROE ~4.7%, ROIC ~4.3% TTM). The Viterra deal is a genuine scale/synergy lever and the strongest part of the bull case, but scale in a commodity trade is table stakes, not a durable competitive advantage. FMP letter rating B-.
Peer set (FMP; market cap): Archer-Daniels-Midland (ADM) $37.0B — the closest direct comp; Tyson Foods (TSN) $21.0B; Fomento Económico Mexicano (FMX) $44.1B; Coca-Cola FEMSA (KOF) $22.6B; Church & Dwight (CHD) $23.4B; McCormick (MKC) $14.4B; Dollar General (DG) $26.1B; Dollar Tree (DLTR) $23.8B; Smithfield (SFD) $9.7B. The agribusiness-relevant comp is ADM; the rest are consumer-defensive peers by sector, not by business model.
9. Management, capital allocation & guidance
- Capital allocation: the defining recent act is the Viterra acquisition — a large, debt-and-equity-funded bet to gain global scale. It roughly doubled revenue and the share count and lifted leverage; the entire near-term thesis hinges on management delivering the promised synergies and deleveraging. Alongside, Bunge pays a dividend ($2.82, ~$459M/yr) and buys back stock ($551M FY25) — but FY25 FCF was negative, so returns to shareholders were funded partly by the balance sheet this year. That's tolerable during integration but must reverse.
- Insider activity: the recent Form 4s (all dated 2026-05-20) are routine director equity awards (A-Award, price $0) — annual board compensation grants, not open-market conviction buys or alarming discretionary sales. No signal either way.
- Management's own guidance: not available. The SEC 8-K (Item 2.02) route returned no usable earnings-release guidance for BG in our automated pull (exhibit too thin), and we do not have management's dated forward outlook in hand. We therefore do not summarize or paraphrase any guidance — none is cited here rather than risk fabricating it. (Management typically frames full-year adjusted EPS on the earnings call; readers should consult the primary release.)
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $1.95 adjusted, revenue ~$22.8B). The key lines: crush margins, Viterra synergy realization, and net-debt trajectory.
- Deleveraging: net-debt/EBITDA falling from the elevated trailing 6.6× toward management's target as EBITDA normalizes — the single most important balance-sheet tell.
- Free cash flow turning positive as Viterra integration capex rolls off — confirms the dividend/buyback are self-funded again.
- Crush & oilseed spreads / biofuel policy: soybean-oil demand from renewable diesel and global crush economics drive the P&L; US/EU biofuel policy is a swing factor.
- South American crop & FX (Brazil/Argentina): harvest size and BRL/ARS moves flow straight through Agribusiness.
Thesis tripwires (what would change the call): synergy targets slipping or being cut; net-debt/EBITDA staying above ~3.5× a year post-close; two consecutive quarters of crush-margin deterioration; or FCF failing to turn positive in FY26 (a dividend-coverage risk).
11. Key risks
- Commodity cyclicality (structural): earnings are driven by crush spreads, crop prices and trade flows Bunge does not control — the FY23 peak → FY25 trough swing shows the amplitude.
- Leverage post-Viterra: trailing net-debt/EBITDA 6.6× and negative FY25 FCF leave less cushion for a down-cycle; deleveraging is a forward assumption, not a fact yet.
- Integration risk: a merger this large can under-deliver synergies or distract management; much of the bull case is synergy execution.
- Thin margins: at ~4.5% gross / ~1% net, small moves in cost or price swing profits hard.
- Dividend coverage: 73% GAAP payout with FY25 FCF negative — safe only if earnings/FCF recover as modeled.
- No expert corroboration: zero Synthos KB coverage means no independent-analyst signal supports (or contests) the call — conviction is structurally low.
- Technical weakness: RSI 19.5 and a death-cross posture mean the price action is actively against the value thesis right now.
12. Verdict, position sizing & monitoring
Watch. Bunge is a competently run, genuinely cheap (~11× FY26E) global agribusiness that just made a transformational Viterra bet — but it is a thin-margin, deeply cyclical, capital-intensive commodity business with no secular growth, no durable moat, elevated post-deal leverage, negative FY25 free cash flow, and zero expert coverage in our KB. The forward earnings recovery and synergy story are real and could reward patient value buyers, and the Street (21 Buy) and our own $120 base (+13%) both point modestly higher — but none of that clears the bar for a Buy rating in a business with these structural characteristics and a tape this weak (RSI 19.5, below both moving averages).
- Sizing: if owned at all, a small value/satellite position (~1–2%), scaled in on weakness or after a clean synergy/deleveraging print — never a core compounder weight.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-07-29 print, with particular attention to synergy realization, net-debt/EBITDA, and FCF. Upgrade path to Buy — Tactical exists if deleveraging and synergies land and the stock is still near current levels; downgrade to Avoid if leverage stays high and crush margins roll over.
- Single biggest risk: a crush/oilseed-margin down-cycle while post-Viterra leverage is still elevated.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $106.46.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage in the Synthos knowledge base; this note cites no
claim_ids and manufactures no conviction. The verdict is fundamentals- and quant-driven only. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Management caveat: no management guidance was available via the SEC 8-K route (exhibit too thin); none is summarized here to avoid fabrication.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").